Gene expression analysis in tubule interstitial compartments reveals candidate agents for IgA nephropathy

Kidney and Blood Pressure Research

Volumn 39, Issue 4, 2014, Pages 361-368

  Wang, Jinling ^a   Cao, Juan ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Gene ontology; Gene pairs; IgA nephropathy; Network; Small molecules

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN A; STEROID HORMONE; THAPSIGARGIN; TRANSCRIPTION FACTOR; MOLECULAR LIBRARY; URINARY TRACT AGENT;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIALLY EXPRESSED GENE; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETIC DATABASE; HAPLOTYPE MAP; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; NUCLEOTIDE SEQUENCE; PROTEINURIA; DRUG EFFECTS; GENETICS; GLOMERULONEPHRITIS, IGA; METABOLISM; MIDDLE AGED; MOLECULAR LIBRARY; NEPHRITIS, INTERSTITIAL; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORKS; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; RENAL AGENTS; SMALL MOLECULE LIBRARIES; YOUNG ADULT;

EID: 84908306858     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355814     Document Type: Article

References (39)

1. Radford MG, Donadio JV, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
2. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 2002;347:738-748.
3. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-165.
4. Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, Sinclair R, Mcneil JJ, Atkins RC: The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 2001;16:1364-1367.
5. Wyatt RJ, Julian BA, Baehler RW, Stafford CC, Mcmorrow RG, Ferguson T, Jackson E, Woodford SY, Miller PM, Kritchevsky S: Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol 1998;9:853-858.
6. Berger J HN: Les depots intercapillaires d'IgA-IgG. Scand J Urol Nephrol 1968;74:594-695.
7. Ponticelli C, Traversi L, Feliciani A, Cesana BM, Banfi G, Tarantino A: Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001;60:1948-1954.
8. Donadio JV, Jr., Grande JP: Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol 1997;8:1324-1332.
9. Liu X, Dewei D, Sun S, Xu G, Liu H, He L, Zhang P: Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther 2014;52:95-102.
10. Reich HN, Tritchler D, Cattran DC, Herzenberg AM, Eichinger F, Boucherot A, Henger A, Berthier CC, Nair V, Cohen CD: A molecular signature of proteinuria in glomerulonephritis. PLoS ONE 2010;5:e13451.
11. Bolstad BM, Irizarry RA, Strand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
12. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S: Bioinformatics and computational biology solutions using R and Bioconductor. 2005, Vol. 746718470, Springer-Verlag, New York.
13. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Series B (Methodological). J Royal Statistical Soc 1995:57:289-300.
14. Janaki C, Joshi RR: Motif detection in Arabidopsis: Correlation with gene expression data. In Silico Biol 2004;4:149-161.
15. Dawson JA, Ye S, Kendziorski C: R/EBcoexpress: an empirical Bayesian framework for discovering differential co-expression. Bioinformatics 2012;28:1939-1940.
16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504.
17. Maere S, Heymans K, Kuiper M: BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005;21:3448-3449.
18. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935.
19. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:709-727.
20. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G: IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000;26:354-357.
21. Ju W, Eichinger F, Bitzer M, Oh J, Mcweeney S, Berthier CC, Shedden K, Cohen CD, Henger A, Krick S: Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol 2009;174:2073-2085.
22. Cohen CD, Frach K, Schlöndorff D, Kretzler M: Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int 2002;61:133-140.
23. Bell G, Gordon A, Lee P, Doig A, Macdonald M, Thomson D, Anderton J, Robson J: Proliferative glomerulonephritis and exposure to organic solvents. Nephron 1985;40:161-165.
24. Porro A, Lomonte C, Coratelli P, Passavanti G, Ferri GM, Assennato G: Chronic glomerulonephritis and exposure to solvents: a case-referent study. Br J Ind Med 1992;49:738-742.
25. Mercado C, Jaimes EA: Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Cur Hypertens Rep 2007;9:66-72.
26. Jaimes EA, Tian R-X, Raij L: Nicotine: the link between cigarette smoking and the progression of renal injury? Am J Physiol Heart Circ Physiol 2007;292:H76-H82.
27. Jain G, Jaimes EA: Nicotine signaling and progression of chronic kidney disease in smokers. Biochem Pharmacol 2013;86:1215-1223.
28. Bronchud M, Howell A, Crowther D, Hopwood P, Souza L, Dexter T: The use of granulocyte colonystimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-125.
29. Von Der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M, Bodrogi I, Albers P, Knuth A, Lippert C: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
30. Aas T, Børresen A-L, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
31. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer J, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-658.
32. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T: Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27:1055-1063.
33. Hahn H, Park YS, Ha IS, Cheong HI, Choi Y: Age-related differences in Adriamycin-induced nephropathy. Pediatr Nephrol 2004;19:761-766.
34. Malarkodi K, Varalakshmi P: Lipoic acid as a rescue agent for adriamycin-induced hyperlipidemic nephropathy in rats. Nutr Res 2003;23:539-548.
35. Rogers TB, Inesi G, Wade R, Lederer W: Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Biosci Rep 1995;15:341-349.
36. Hakii H, Fujiki H, Suganuma M, Nakayasu M, Tahira T, Sugimura T, Scheuer P, Christensen S: Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in twostage mouse skin carcinogenesis. J Cancer Res Clin Oncol 1986;111:177-181.
37. Thastrup O, Cullen PJ, Drøbak B, Hanley MR, Dawson AP: Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2 (+)-ATPase. Proc Natl Acad Sci USA 1990;87:2466-2470.
38. Dombroski BA, Nayak RR, Ewens KG, Ankener W, Cheung VG, Spielman RS: Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. Am J Hum Genet 2010;86:719-729.
39. Sinha R, Shekhar H, Sharma N, Titiyal JS, Vajpayee RB: Posterior capsular opacification: A review. Indian J Ophthalmol 2013;61:371.